Grand challenges in modulating the immune response with RNAi nanomedicines

Meir Goldsmith, Shoshy Mizrahy, Dan Peer

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


RNAi is a ubiquitous and highly specific, endogenous, evolutionarily conserved mechanism of gene silencing. RNAi holds great promise as a novel therapeutic modality. Despite the rapid progress in the understanding and utilization of RNAi in vitro, the application of RNAi in vivo has been met with great difficulties, mainly in the delivery of these molecules into specific cell types. Here, we describe the major systemic nanomedicine platforms that have been developed. Focus is given to the development of new strategies to target subsets of leukocytes, which are among the most difficult cells to transduce with RNAi. Finally, we discuss the hurdles and potential opportunities for in vivo manipulation of the immune response utilizing RNAi nanomedicines.

Original languageEnglish (US)
Pages (from-to)1771-1785
Number of pages15
Issue number10
StatePublished - Dec 2011


  • immune response
  • leukocytes
  • liposomes
  • nanomedicine
  • RNAi

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development


Dive into the research topics of 'Grand challenges in modulating the immune response with RNAi nanomedicines'. Together they form a unique fingerprint.

Cite this